Education
About Us
Working with TipRanks
Follow Us
RaySearch Laboratories AB Class B (RSLBF)
:RSLBF
RSLBF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.60 - $26.36
Previous CloseN/A
Volume27.00
Average Volume (3M)39.00
Market Cap
$798.44M
Enterprise Value$5.37B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)162.66M
Price to Earnings (P/E)40.9
Beta0.94
Next Earnings
May 09, 2025EPS Estimate
0.13Next Dividend Ex-Date
May 23, 2025Dividend Yield0.28%
Share Statistics
EPS (TTM)0.56
Shares Outstanding26,627,798
10 Day Avg. Volume116
30 Day Avg. Volume39
Standard Deviation0.19
R-Squared0.14
Alpha0.01
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)N/A
Price to Sales (P/S)3.28
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
RaySearch Laboratories AB News
PremiumCompany Announcements
RaySearch Laboratories Reports Record Year in 2024
PremiumCompany Announcements
RaySearch Laboratories Reports Strong Q3 2024 Growth
PremiumPre-Earnings
Is RSLBF a Buy, Before Earnings?
PremiumPre-Earnings
Is RSLBF a Buy, Before Earnings?---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.67% Mutual Funds
― Other Institutional Investors
98.08% Public Companies and
Individual Investors
RSLBF FAQ
What was RaySearch Laboratories AB Class B’s price range in the past 12 months?
RaySearch Laboratories AB Class B lowest stock price was $9.60 and its highest was $26.36 in the past 12 months.
What is RaySearch Laboratories AB Class B’s market cap?
RaySearch Laboratories AB Class B’s market cap is $798.44M.
When is RaySearch Laboratories AB Class B’s upcoming earnings report date?
RaySearch Laboratories AB Class B’s upcoming earnings report date is May 09, 2025 which is in 68 days.
How were RaySearch Laboratories AB Class B’s earnings last quarter?
RaySearch Laboratories AB Class B released its earnings results on Feb 21, 2025. The company reported $0.164 earnings per share for the quarter, beating the consensus estimate of $0.124 by $0.04.
Is RaySearch Laboratories AB Class B overvalued?
According to Wall Street analysts RaySearch Laboratories AB Class B’s price is currently Overvalued.
Does RaySearch Laboratories AB Class B pay dividends?
RaySearch Laboratories AB Class B pays a Annually dividend of $0.282 which represents an annual dividend yield of 0.28%. See more information on RaySearch Laboratories AB Class B dividends here
What is RaySearch Laboratories AB Class B’s EPS estimate?
RaySearch Laboratories AB Class B’s EPS estimate is 0.13.
How many shares outstanding does RaySearch Laboratories AB Class B have?
RaySearch Laboratories AB Class B has 26,627,798 shares outstanding.
What happened to RaySearch Laboratories AB Class B’s price movement after its last earnings report?
RaySearch Laboratories AB Class B reported an EPS of $0.164 in its last earnings report, beating expectations of $0.124. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of RaySearch Laboratories AB Class B?
Currently, no hedge funds are holding shares in RSLBF
---
Company Description
RaySearch Laboratories AB Class B
RaySearch Laboratories AB is a Sweden-based medical technology company. The company develops advanced software solutions for radiation therapy. RaySearch markets the proprietary treatment planning system RayStation. Its products are distributed through licensing agreements with medical technology companies. Its geographic segments consist of Sweden, North America, Asia, Europe and the rest of the world. The company generates most of its sales from the North America.
---
RSLBF Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
RaySearch had a strong Q3 2024 with record-breaking sales and improved operating profit and margin. Key strategic milestones were achieved, such as RayCare's integration with Varian TrueBeam. Despite these successes, there were some challenges, including a decrease in support order intake and lower cash flow from operations. However, the overall sentiment of the call indicates a positive outlook for future growth, supported by increased financial targets.Read More>---
Technical Analysis
Veracyte
―
Heron Therapeutics
―
Kala Pharmaceuticals
―
QuidelOrtho
―
Fulgent Genetics
―
Abbott Laboratories
―
---